RANKL Inhibition Reduces Cardiac Hypertrophy in

Area of Science:

• Biomedical Research
• Cardiovascular Science
• Musculoskeletal Disorders

Background:

• Cardiomyopathy is a primary cause of mortality in Duchenne muscular dystrophy (DMD).
• The receptor activator of nuclear factor κB ligand (RANKL) and its receptor (RANK) pathway is implicated in muscle and bone health.
• RANKL and RANK are present in cardiac tissue, suggesting a role in heart function.

Purpose of the Study:

• To investigate the efficacy of anti-RANKL treatment in preventing cardiac hypertrophy and dysfunction in dystrophin-deficient (mdx) mice.
• To explore the molecular mechanisms underlying the cardioprotective effects of anti-RANKL therapy.

Main Methods:

• Treatment of mdx mice with an anti-RANKL agent.
• Assessment of cardiac structure and function, including left ventricular (LV) hypertrophy and heart mass.
• Analysis of key signaling pathways (NFκB, PI3K) and calcium handling proteins (SERCA, RyR, FKBP12).

Main Results:

• Anti-RANKL treatment significantly reduced LV hypertrophy and heart mass in mdx mice.
• Cardiac function was preserved in mdx mice receiving anti-RANKL treatment.
• The treatment inhibited NFκB and PI3K pathways and improved calcium handling markers (SERCA activity, RyR, FKBP12, SERCA2a expression).

Conclusions:

• Anti-RANKL therapy demonstrates potential in preventing cardiac hypertrophy progression in DMD.
• This therapeutic strategy may help maintain cardiac function in individuals with DMD.
• Preliminary human data suggests denosumab may reduce left ventricular hypertrophy in DMD patients.